Nektar Therapeutics (NKTR)

Trade NKTR now with
8/16/2022 8:35:51 AM Nektar : Publication Of Preclinical Data For NKTR-255& Observed Improvement Of NK Cell Function In Multiple Myeloma
8/4/2022 4:21:50 PM Nektar Therapeutics Q2 Loss/share $0.85 Vs. Loss $0.69 Year Ago
7/1/2022 6:31:59 AM Nektar Promotes Jillian Thomsen To SVP And CFO
5/5/2022 4:17:23 PM Nektar Therapeutics Q1 Loss/share $0.49 Vs. Loss $0.68 Year Ago
4/14/2022 5:05:28 PM Nektar, Bristol Myers Announce Update On Clinical Development Program For Bempegaldesleukin In Combination With Opdivo
2/28/2022 4:21:19 PM Nektar Therapeutics Q4 Loss/share $0.79 Vs. Loss $0.65 Year Ago
12/13/2021 9:05:23 AM Nektar Therapeutics Presents Data For NKTR-255 In Patients With Relapsed/Refractory Hematologic Malignancies
11/30/2021 8:05:29 AM Nektar Therapeutics Announces Data Presentations For Its Immuno-Oncology Programs
11/15/2021 8:32:53 AM Nektar Therapeutics Appoints Diana Brainard As Independent Director To Board